Welcome to our dedicated page for Outlook Therapeutics SEC filings (Ticker: OTLK), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Outlook Therapeutics, Inc. filings document material events for a Nasdaq-listed biopharmaceutical company focused on ONS-5010/LYTENAVA for wet AMD and other retina-disease applications. The company’s 8-K disclosures cover FDA-related communications for its biologics license application, including Complete Response Letter follow-up, Type A meeting activity and formal dispute-resolution matters.
Regulatory filings also describe capital-structure activity involving common stock, warrants, registered and unregistered securities, note financing and amendments to debt instruments. Governance records include shareholder voting results, board composition changes, proxy-related matters, Nasdaq-listed common stock information, exhibits and risk-factor or material-agreement disclosures tied to financing and regulatory developments.
Outlook Therapeutics director Yezan Munther Haddadin bought 29,000 shares of Common Stock in an open-market purchase. The shares were acquired at an average price of $0.8326 per share. Following this transaction, he directly holds a total of 66,167 Outlook Therapeutics shares.
Outlook Therapeutics’ major shareholder GMS Ventures and Investments updated its ownership following a May 2026 financing. GMS Ventures bought 8,539,709 shares at $0.5855 per share for about $5.0 million in a registered direct offering that closed on May 29, 2026.
In connection with this deal, warrants previously issued to GMS Ventures for 15,488,570 shares had their weighted average exercise price reduced from $1.78 to $0.5855 per share, with other terms unchanged. After these transactions, GMS Ventures beneficially owns 37,580,638 shares (including the warrants), or about 22.9% of Outlook Therapeutics’ common stock based on 148,587,119 shares outstanding immediately after the offering.
Outlook Therapeutics received a new investment from GMS Ventures & Investments, which bought 8,539,709 shares of common stock at $0.5855 per share in a registered direct offering for a total purchase price of about $5.0 million. Following this purchase, GMS Ventures reported indirect ownership of 22,092,068 common shares.
The filing also shows amendments to multiple warrant series held by GMS Ventures. Existing warrants with exercise prices of $2.26 and $1.40 per share were cancelled and replaced with new warrants covering the same share amounts at a reduced exercise price of $0.5855 per share, with expirations in 2030. The transactions are reported as cancellations of old warrants and acquisitions of new ones rather than exercises.
All securities are held of record by GMS Ventures. Ghiath M. Sukhtian controls GMS Ventures and may be deemed to share voting and investment power, but the reporting persons disclaim beneficial ownership except to the extent of any pecuniary interest.
Outlook Therapeutics is calling a special stockholder meeting on July 16, 2026 to vote on three capital-structure proposals. Stockholders are asked to approve issuing common shares upon exercise of private placement, placement agent and amended warrants, to increase authorized common shares from 260 million to 600 million, and to authorize a 1‑for‑10 to 1‑for‑50 reverse stock split with a proportional authorized share reduction. The company explains these steps support needed fundraising, compliance with Nasdaq’s $1.00 minimum bid price and access to up to roughly $6.1 million of additional warrant proceeds, but also highlight potential dilution and reverse-split risks for existing holders.
Outlook Therapeutics, Inc. filed an 8-K and issued a press release announcing that it has resubmitted its Biologics License Application (BLA) to the U.S. Food and Drug Administration for ONS-5010/LYTENAVA™ (bevacizumab-vikg) to treat neovascular age-related macular degeneration.
The company previously successfully appealed a December 2026 Complete Response Letter, after which the FDA Office of New Drugs concluded that substantial evidence of effectiveness has been established and that no additional trials are required. The decision directed FDA staff to work with Outlook Therapeutics to finalize product labeling.
The resubmission is classified as a Class 1 resubmission, with a PDUFA date and FDA decision expected within 60 days of FDA’s receipt. ONS-5010/LYTENAVA™ already holds centralized Marketing Authorization in the EU and UK for wet AMD, and commercial launch has begun in Germany, Austria, and the UK.
Outlook Therapeutics, Inc. completed a registered direct offering of 8,539,709 shares of its common stock, $0.01 par value per share, to GMS Ventures and Investments. The shares were issued under an existing shelf registration statement on Form S-3 (File No. 333-278340).
The transaction was executed pursuant to a securities purchase agreement dated May 28, 2026, and used the company’s base prospectus and a prospectus supplement. Legal opinions and related consents from Cooley LLP were filed as exhibits in connection with this equity financing.
Outlook Therapeutics is offering 8,539,709 shares of common stock at $0.5855 per share to a single accredited institutional investor.
In connection with this offering and effective upon closing, the company will amend outstanding warrants to purchase up to an aggregate of 15,488,570 shares so that the amended warrants have a reduced exercise price of $0.5855 per share. The offering is a direct sale without underwriters and delivery is expected on or about May 29, 2026.
The filing states the company had $7.7 million in cash and cash equivalents as of March 31, 2026, expects approximately $4.9 million net proceeds from this offering and estimates combined funds will fund operations into September 2026. The company also reports that the FDA granted an appeal after a Formal Dispute Resolution meeting and that it expects to resubmit the BLA for ONS-5010/LYTENAVA in June 2026.
Outlook Therapeutics, Inc. agreed to a registered direct offering with GMS Ventures and Investments for 8,539,709 shares of common stock at $0.5855 per share, for expected gross proceeds of approximately $5.0 million before expenses. The transaction is expected to close on or about May 29, 2026, with proceeds intended for working capital and general corporate purposes.
In connection with this financing, the company entered into a warrant amendment with the same investor to reduce the exercise price of outstanding warrants to purchase up to 15,488,570 shares of common stock from a weighted average of $1.78 to $0.5855 per share, effective upon closing. Both the purchase agreement and warrant amendment include customary terms, conditions, and indemnification provisions and are tied to an existing effective Form S-3 registration statement and related prospectus supplement.
Outlook Therapeutics, Inc. director Sukhtian Faisal Ghiath reported an open-market purchase of 122,174 shares of Common Stock at an average price of $0.4093 per share. Following this transaction, he directly owns a total of 125,574 Common Stock shares.
Outlook Therapeutics, Inc. director Yezan Munther Haddadin reported an open-market purchase of the company’s Common Stock. On May 26, 2026, he bought 34,000 shares at $0.44 per share. Following this transaction, he directly owns 37,167 shares of Outlook Therapeutics common stock.